Protocol to evaluate fasting metabolism and its relationship to the core circadian clock in mice.
Sun J, DeBosch BJ.
STAR Protoc · research-article; journal article · DOI 10.1016/j.xpro.2025.103660 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för devimistat. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
27 hitsThe function and mechanism of clinical trial agent CPI-613 in multiple myeloma.
Wang H, Zhang Y, Jiang Y, Xiang R, Gong H, Gong Y, Xu H, Ma Z, Xie Y, Zhu Y, Hu B, He X, Liu J, Zhang J, Xiao X.
Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2024.116717Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors.
Udumula MP, Rashid F, Singh H, Pardee T, Luther S, Bhardwaj T, Anjaly K, Piloni S, Hijaz M, Gogoi R, Philip PA, Munkarah AR, Giri S, Rattan R.
J Ovarian Res · research-article; journal article · DOI 10.1186/s13048-024-01546-6Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.
Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E.
J Clin Oncol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.23.02659Inhibition of pyruvate dehydrogenase accelerates anaerobic glycolysis under postmortem simulating conditions.
Taylor MJ, Stafford CD, Buhler JF, Dang DS, Alruzzi MA, Najm TA, Gerrard SD, Thornton KJ, van Vliet S, El-Kadi SW, Gerrard DE, Matarneh SK.
Meat Sci · journal article · DOI 10.1016/j.meatsci.2024.109510OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma.
Nguyen TT, Torrini C, Shang E, Shu C, Mun JY, Gao Q, Humala N, Akman HO, Zhang G, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD.
JCI Insight · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.172565Inducing Melanoma Cell Apoptosis by ERp57/PDIA3 Antibody in the Presence of CPI-613 and Hydroxychloroquine.
Ichiki N, Saigo C, Hanamatsu Y, Iwata H, Takeuchi T.
J Cancer · research-article; journal article · DOI 10.7150/jca.92252Potassium ion efflux induces exaggerated mitochondrial damage and non-pyroptotic necrosis when energy metabolism is blocked.
Xu R, Yuan LS, Gan YQ, Lu N, Li YP, Zhou ZY, Zha QB, He XH, Wong TS, Ouyang DY.
Free Radic Biol Med · research support, non-u.s. gov't; journal article · DOI 10.1016/j.freeradbiomed.2023.12.029Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V.
Clin Cancer Res · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-23-0036Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Mangieri CW, Valenzuela CD, Solsky IB, Erali RA, Pardee T, Lima CMSR, Howerton R, Clark CJ, Shen P.
J Surg Oncol · clinical trial, phase i; journal article · DOI 10.1002/jso.27365Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy.
Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA, Philip PA, Tsai S, Luther S, Hall WA, Azmi AS.
Adv Radiat Oncol · research-article; journal article · DOI 10.1016/j.adro.2022.101122Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Guardado Rivas MO, Stuart SD, Thach D, Dahan M, Shorr R, Zachar Z, Bingham PM.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0269620Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.
Kumstel S, Schreiber T, Goldstein L, Stenzel J, Lindner T, Joksch M, Zhang X, Wendt EHU, Schönrogge M, Krause B, Vollmar B, Zechner D.
PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0266601Development and validation of an LC-MS/MS method for determination of a novel anticancer agent (CPI-613) in human plasma.
Reddy NR, Reddy V, Boteju A, Boteju L, Voelker T, Liu S, Hu K.
Bioanalysis · journal article · DOI 10.4155/bio-2021-0270In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human.
Reddy VB, Boteju L, Boteju A, Shen L, Kassahun K, Reddy N, Sheldon A, Luther S, Hu K.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.121.000726Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer.
Lang L, Wang F, Ding Z, Zhao X, Loveless R, Xie J, Shay C, Qiu P, Ke Y, Saba NF, Teng Y.
J Exp Clin Cancer Res · research-article; journal article · DOI 10.1186/s13046-021-02207-yThe Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner.
Arnold C, Demuth P, Seiwert N, Wittmann S, Boengler K, Rasenberger B, Christmann M, Huber M, Brunner T, Linnebacher M, Fahrer J.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-21-0393Smart Design of Mitochondria-Targeted and ROS-Responsive CPI-613 Delivery Nanoplatform for Bioenergetic Pancreatic Cancer Therapy.
Zhang YM, Xia M, Ao R, Gao LX, Tang Y, Huang JH, Luo YF, Chen ZZ, Wang BC, Huang Z.
Nanomaterials (Basel) · research-article; journal article · DOI 10.3390/nano11112875An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio).
Hala D, Faulkner P, He K, Kamalanathan M, Brink M, Simons K, Apaydin M, Hernout B, Petersen LH, Ivanov I, Qian X.
Comp Biochem Physiol C Toxicol Pharmacol · journal article · DOI 10.1016/j.cbpc.2021.109084CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling.
Gao L, Xu Z, Huang Z, Tang Y, Yang D, Huang J, He L, Liu M, Chen Z, Teng Y.
J Exp Clin Cancer Res · research-article; journal article · DOI 10.1186/s13046-020-01579-xThe Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells.
Bellio C, DiGloria C, Spriggs DR, Foster R, Growdon WB, Rueda BR.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers11111678A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E.
Future Oncol · clinical trial protocol; review-article; journal article · DOI 10.2217/fon-2019-0209Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts.
Mordhorst BR, Kerns KC, Schauflinger M, Zigo M, Murphy SL, Ross RM, Wells KD, Green JA, Sutovsky P, Prather RS.
Sci Rep · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-019-45850-4Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma.
Egawa Y, Saigo C, Kito Y, Moriki T, Takeuchi T.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0198940A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL.
Clin Cancer Res · research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-17-2282Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.
Lancet Oncol · research-article; clinical trial, phase i; journal article · DOI 10.1016/s1470-2045(17)30314-5A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.
PLoS One · clinical trial, phase ii; research-article; journal article · DOI 10.1371/journal.pone.0164244